Hexagon Capital Partners LLC Has $894,000 Stock Holdings in Amgen Inc. (NASDAQ:AMGN)

Hexagon Capital Partners LLC lifted its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 3.3% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 3,104 shares of the medical research company’s stock after purchasing an additional 100 shares during the quarter. Hexagon Capital Partners LLC’s holdings in Amgen were worth $894,000 as of its most recent SEC filing.

Several other hedge funds also recently modified their holdings of AMGN. OFI Invest Asset Management acquired a new position in shares of Amgen during the 3rd quarter worth $26,000. Briaud Financial Planning Inc acquired a new position in shares of Amgen during the 3rd quarter worth $26,000. BOK Financial Private Wealth Inc. acquired a new position in shares of Amgen during the 4th quarter worth $29,000. Providence Capital Advisors LLC acquired a new position in shares of Amgen during the 3rd quarter worth $30,000. Finally, Planned Solutions Inc. acquired a new position in shares of Amgen during the 4th quarter worth $30,000. Institutional investors and hedge funds own 76.50% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts recently issued reports on the stock. Truist Financial reiterated a “buy” rating and issued a $320.00 target price on shares of Amgen in a research note on Friday, April 12th. Royal Bank of Canada reiterated an “outperform” rating and issued a $329.00 target price on shares of Amgen in a report on Wednesday, April 3rd. The Goldman Sachs Group raised their price target on shares of Amgen from $313.00 to $350.00 and gave the stock a “buy” rating in a research report on Wednesday, February 7th. Raymond James initiated coverage on shares of Amgen in a research report on Thursday, March 28th. They issued a “market perform” rating on the stock. Finally, UBS Group decreased their price target on shares of Amgen from $314.00 to $284.00 and set a “neutral” rating on the stock in a research report on Wednesday, April 17th. Ten investment analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. According to MarketBeat, Amgen currently has a consensus rating of “Moderate Buy” and an average price target of $297.40.

Amgen Price Performance

NASDAQ:AMGN traded down $2.44 on Tuesday, reaching $273.94. The stock had a trading volume of 2,476,256 shares, compared to its average volume of 2,816,730. The company has a market capitalization of $146.94 billion, a P/E ratio of 21.93, a price-to-earnings-growth ratio of 2.61 and a beta of 0.58. Amgen Inc. has a 1-year low of $211.71 and a 1-year high of $329.72. The company has a quick ratio of 1.13, a current ratio of 1.65 and a debt-to-equity ratio of 10.14. The stock has a fifty day moving average price of $274.76 and a 200-day moving average price of $281.37.

Amgen (NASDAQ:AMGN) last released its quarterly earnings results on Tuesday, February 6th. The medical research company reported $4.71 EPS for the quarter, beating analysts’ consensus estimates of $4.66 by $0.05. The firm had revenue of $8.20 billion for the quarter, compared to analyst estimates of $8.13 billion. Amgen had a net margin of 23.83% and a return on equity of 154.27%. The company’s revenue for the quarter was up 19.8% compared to the same quarter last year. During the same period in the previous year, the business earned $4.09 earnings per share. Research analysts forecast that Amgen Inc. will post 19.43 EPS for the current year.

Amgen Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, June 7th. Shareholders of record on Friday, May 17th will be paid a $2.25 dividend. This represents a $9.00 dividend on an annualized basis and a dividend yield of 3.29%. The ex-dividend date is Thursday, May 16th. Amgen’s dividend payout ratio is presently 72.06%.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.